Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2109MR)

This product GTTS-WQ2109MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2109MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9497MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ1458MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ12957MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ10168MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ8873MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ12083MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ13378MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ9567MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW